Nluc Reporter Cell Line - NALM-6

NALM-6 is a widely utilized human B-cell acute lymphoblastic leukemia (B-ALL) cell line, originally established from the peripheral blood of a 19-year-old male patient during clinical relapse. Growing in suspension with a classic lymphoblast morphology, NALM-6 is renowned in hematological research for its robust expression of critical B-cell surface antigens, most notably CD19, CD10, and CD22. The Nluc Reporter Cell Line - NALM-6 elevates this foundational leukemia model through the stable genetic integration of the NanoLuc (Nluc) reporter gene. NanoLuc is a highly engineered, exceptionally compact (19.1 kDa) luciferase enzyme derived from the deep-sea shrimp Oplophorus gracilirostris. When catalyzed by its specific substrate, furimazine, it generates a sustained, high-intensity luminescent signal that is often up to 100 times brighter than conventional firefly luciferase. Most importantly, the engineered Nluc-NALM-6 cells strictly retain the biological identity of the parental line, preserving its exact suspension growth dynamics and critical CD19 surface expression, which is essential for ensuring biological authenticity and translational relevance in subsequent research.

The ultra-bright luminescent output of the Nluc-NALM-6 cell line makes it a premier tool for both in vitro analytics and advanced preclinical in vivo modeling, particularly in the rapidly expanding field of adoptive cell therapy. In standard laboratory environments, the intense NanoLuc signal facilitates highly sensitive quantification of cell viability and proliferation. This provides an ideal platform for evaluating the precise cytotoxicity of targeted immunotherapies, such as CD19-directed CAR-T cells, natural killer (NK) cell therapies, and bispecific antibodies, even at very low effector-to-target ratios. In preclinical animal studies, this reporter line serves as the gold standard for establishing systemic, disseminated models of human B-ALL. Following intravenous administration into immunodeficient mice, the Nluc-NALM-6 cells naturally home to and engraft within the bone marrow, spleen, and frequently the central nervous system (CNS). The remarkable sensitivity of NanoLuc-driven bioluminescence imaging (BLI) enables researchers to non-invasively detect minimal disease burden, map early systemic dissemination, and dynamically track the long-term eradication or relapse of leukemic cells in living subjects without relying solely on survival endpoints.